Protalix BioTherapeutics, Inc. (DE) revenue breakdown overview

Protalix BioTherapeutics, Inc. (DE) revenue for the last year amounted to 53.40 M USD, the most of which — 53.40 M USD — came from its highest performing source at the moment, Recombinant Therapeutic Proteins, the year earlier bringing 65.49 M USD. The greatest contribution to the revenue figure was made by Italy — last year it brought Protalix BioTherapeutics, Inc. (DE) 29.33 M USD, and the year before that — 17.50 M USD.